Northbrook Star By Karie Angell Luc July 23, 2012 6:08AM

The longest day of golf has a hole-in-goal of shortening the distance to finding a cure for pediatric brain tumors.

Green Acres Country Club of Northbrook at 916 Dundee Road will host 24 players Monday who will take a swing at 1,400 combined holes of golf to raise $60,000 for pediatric tumor research via the Chicago philanthropicorganization Partnership for Cures.

“There is a personal connection,’ said Steve Goldsher of Northbrook, a print procurement consultant and also Partnership for Cures (volunteer) executive board member.  “Every year (18 year history), we choose a research project to fund with this year being for recurrent pediatric brain tumors.  This year’s research project was inspired by my relationship with the Wehrs and Pete (Weiss) and his family.”

Newsweek Magazine

May 14, 2010 

How the road from promising scientific breakthrough to real-world remedy has become all but a dead end.

By Sharon Begley and Mary Carmichael

From 1996 to 1999, the U.S. food and Drug Administration approved 157 new drugs. In the comparable period a decade later—that is, from 2006 to 2009—the agency approved 74. Not among them were any cures, or even meaningfully effective treatments, for Alzheimer's disease, lung or pancreatic cancer, Parkinson's disease, Huntington's disease, or a host of other afflictions that destroy lives.

Newsweek June 15, 2009

by Sharon Begley

Now that President Obama has almost all of his top science picks in place—from the Department of Energy to the FDA—the lack of an appointee for director of the Nation-al Institutes of Health is standing out like a creationist at an evolution conference. I hope the delay means Obama has grasped the need for, and the difficulty of finding, a powerful director who can get beyond the rhetoric about moving discoveries out of the lab and make it a reality. That hasn't happened yet, six years after a much-ballyhooed NIH "road map" declared such bench-to-bedside research a priority and vowed to reward risk-taking, innovative studies, not the same old incremental research that has produced too few cures.  Read full article

Applied Clinical Trials Online

June 7, 2016

By Bruce Bloom

The case for supporting off-label use or commercialization in drugs for “unsolved” diseases.

There are over 7,000 “unsolved” diseases for which patients have no universally successful treatment. There are also thousands of generic drugs that can be repurposed to help these patients. Built on knowledge from scientific discoveries, anecdotal evidence, and/or bioinformatics, generic drug repurposing research can often lead to quick and affordable development of “new” medical solutions. Once a generic drug repurposing opportunity has been identified, a key issue is whether the clinical trial validation should focus on supporting a path to commercialization or to physician off-label use. The direction of focus depends on the entity supporting the clinical trial development.


Read the full article here

Sign up for our eNewsletter today!


First Name


Cures Within Reach

Illinois Science+Technology Park

8025 Lamon Avenue, Suite 440

Skokie, IL 60077



Sunday the 25th. copyright 2015 Cures Within Reach.